The human BTC tissues were collected under approval of the Ethical Committee for Clinical Research at Azienda Ospedaliera Universitaria, Modena, Italy (ID 465/2018/SPER/AOUMO). The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as per ethical approval given by the institutional review board. Written informed consent was obtained from all participants. Diagnosis of BTC was established on radiological findings and was pathologically proven in all patients. Inclusion Criteria, Subject Demographics, Sex and Biological Variables and Clinicopathological characteristics were shown in Table S1 .
Disease recurrence was defined as the presence of imaging‐proven disease.
Total RNA was extracted from the FFPE (Formalin-Fixed-Paraffinn-Embedded) samples from 62 tumor and the matched nontumor component after microscopic dissection (TableS1 ). MiRNAs were extracted from FFPE tissues before the beginning of therapy and at disease progression through Maxwell® RSC RNA FFPE Kit (Promega, Madison, WI, USA) and processed with Maxwell® RSC Instruments (Promega, Madison, WI, USA) according to the manufacturer’s instructions [21 (link), 22 (link)].
Disease recurrence was defined as the presence of imaging‐proven disease.
Total RNA was extracted from the FFPE (Formalin-Fixed-Paraffinn-Embedded) samples from 62 tumor and the matched nontumor component after microscopic dissection (Table
Free full text: Click here
